Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036341 (schizophrenia)
 60,220 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

While numerous studies have concluded that high expressed emotion (EE) in relatives predicts relapse in schizophrenia, other aspects of patient outcome have not been well studied. Our purpose was to determine the extent to which family dynamics and expressed emotion may predict variance in patient social adjustment when controlling for symptom severity. Sixty-nine schizophrenic outpatients and 108 of their relatives participated. Relatives' EE was assessed, and they were administered the FACES III for perceptions of family cohesion and adaptability. Patients were interviewed at about the same time as their relatives and again 9 months later with the Social Adjustment Scale (SAS-II) and the BPRS. Between 9% and 58% of variance in each of the five SAS scales was explained by selected EE and family dynamics scales, while symptom severity was held constant. Among the results, it was found that better social adjustment in patients was associated with less family adaptability, and with greater emotional overinvolvement in relatives. Adjustment of patients in the work role was associated with more Critical Comments from mothers. In conclusion, some aspects of high EE are associated with better social adjustment in schizophrenic patients.
 ...
PMID:Expressed emotion, family dynamics and symptom severity in a predictive model of social adjustment for schizophrenic young adults. 771 Sep 92

Concentrations of the alpha-subunits of GTP-binding protein, Go (Go alpha) and of Gi2 (Gi2 alpha) in 6 areas (the hippocampus, parahippocampus, putamen, caudate head, orbital frontal cortex, and lateral temporal cortex) of control and schizophrenic postmortem brains were investigated using the highly sensitive enzyme immunoassay method. There was a significant decrease in Go alpha in the hippocampus and caudate head of the right hemisphere in schizophrenic patients compared to controls; the ANOVA (a general linear model; SAS Type II) demonstrated a significant diagnosis x side interaction only in the hippocampus. In other areas of the brain, analysis by grouping under diagnosis, side, age, gender, and postmortem delay showed no significant deviations in Go alpha between controls and schizophrenics. The concentrations of Gi2 alpha did not differ significantly in any area. These findings contrasted with the results yielded by ADP-ribosylation, which showed decreased pertussis toxin ADP-ribosylated amounts in the hippocampus and putamen of the contralateral (left) hemisphere. Some abnormal receptor-Go or Gi 1 signalling in hippocampus, putamen or caudate head may be involved in the pathogenesis of schizophrenia.
 ...
PMID:Reduced concentrations of the alpha-subunit of GTP-binding protein Go in schizophrenic brain. 786 71

This study verifies the effect of the neuroleptic treatment teaching module, the French translation of the Medication Management Module produced by the social skills training programs. Twenty patients from an outpatient clinic (with schizophreniform or schizoaffective schizophrenia) were assigned at random to a test group (n = 10) or a control group (n = 10). The pre-test evaluation found that the two groups were the same with regard to 13 significant parameters. The experimenters used French translations of well-known instruments, and the double-blind method was applied to their respective observations throughout the study. Results were obtained by applying the neuroleptic treatment teaching module three hours per week for two to three months. The post-test evaluation revealed that patients who had been exposed to the education module had an improved understanding of schizophrenia and the medication required to treat it than patients who had not been exposed. The dose of medication prescribed between pre- and post-test evaluations were able to more effectively stabilize patients who had received education than patients who had not. Nevertheless, the education module continues to have no significant effect on the symptomatology (according to the Brief Psychiatric Rating Scale) and final SAS-II social scores of schizophrenics.
 ...
PMID:[Effect of patient education on neuroleptic treatment of young psychotic patients]. 790

We evaluated the construct validity of the revised Social Anhedonia Scale (SAS; Mishlove & Chapman, 1985) through an examination of the Minnesota Multiphasic Personality Inventory (MMPI) profiles produced by extreme scorers on the SAS. The MMPI classification strategy employed by Moldin, Gottesman, and Erlenmeyer-Kimling (1987) was used to group profiles with regard to their specificity to schizophrenia spectrum disorders. Of 1,124 college students, 58 females and 60 males had elevated SAS scores. Thirty-five percent of the males and 24.14% of the females produced MMPI profiles within the Moldin et al. classification scheme. Another 27.59% of females and 23.33% of males had profiles that are sometimes associated with schizotypal attributes. Thus, 41.67% of high-SAS males and 48.28% of high-SAS females have MMPI profiles that are unlikely to be associated with a heightened risk for schizophrenia. Because only a subset of socially anhedonic subjects produced schizophrenia spectrum MMPI profiles, it appears that the SAS, in isolation, should not be used to identify individuals at risk for schizophrenia. The revised SAS, like its predecessor, does not appear uniquely related to the schizophrenia spectrum. Unlike Mishlove and Chapman (1985), we did not find a gender difference among subjects.
 ...
PMID:Use of the MMPI to assess the construct validity of the revised Social Anhedonia Scale as an index of schizotypy. 847 62

The purpose of this study was to evaluate the utility of a self-report measure of social functioning as an outcome measure for older schizophrenia patients. Sixty-five schizophrenia patients and 39 healthy controls, ranging in age from 45 to 81 years, were evaluated using a modified Social Adjustment Scale (SAS-M), Scales for Assessment of Positive and Negative Symptoms, Depression Subscale of the Brief Symptom Inventory, Mini-Mental State Examination, Dementia Rating Scale, measures of social support, and measures of background variables. Compared with controls, fewer patients with schizophrenia engaged in social roles, were married, were parents, or held jobs. Moreover, patients were more impaired in overall functioning, specifically in the domains of social/leisure, extended family, and marital roles than controls. Impairments in most roles were correlated with greater severity of symptoms, but not with degree of cognitive impairment, social environment, or background characteristics. The SAS-M is a useful addition to psychosocial batteries; however, the self-report format may not reflect others' perception of functioning.
 ...
PMID:Self-reported social functioning among older patients with schizophrenia. 941 49

This cross-sectional study examined the relationships between cognitive functioning, social functioning, and social problem solving in a sample of 30 outpatients with schizophrenia. The cognitive battery included measures of verbal ability, memory, executive functioning, visual-spatial ability, and attention. Social functioning was assessed with the Social Dysfunction Index (SDI) and the Social Adjustment Scale-II (SAS-II). Social problem solving was assessed with a video-based test, the Assessment of Interpersonal Problem-solving Skills (AIPSS). No significant association was found between social functioning as assessed by the SDI and the SAS-II and cognitive functioning. In multiple regression analyses, a measure of attention, the auditory Continuous Performance Test was a significant predictor of processing and sending skills, as assessed by the AIPSS. (F = 16.37, 9.23, p < 0.001).
 ...
PMID:Relationship between cognitive and social dysfunction in schizophrenia. 982 77

Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia. The study was double-blind and involved 228 patients allocated, after a 3-6-day wash-out period, to amisulpride 800 mg (n = 115) or risperidone 8 mg (n = 113) for 8 weeks. Both treatments produced a marked improvement in schizophrenic symptomatology. Decreases in mean BPRS total score were 17.7 +/- 14.9 for amisulpride and 15.2 +/- 13.9 for risperidone, and all of the individual factors on the BPRS showed a numerically greater improvement in the amisulpride than in the risperidone patients. Both treatments were equally effective against positive symptoms on the PANSS positive syndrome subscale; however, there was a trend in favor of greater improvement in negative symptoms assessed on the PANSS negative subscale in patients receiving amisulpride with a decrease of 6.9 +/- 7.5 vs. 5.3 +/- 6.6 for risperidone (P = 0.09). Both drugs demonstrated good safety profiles, and scores on neurological scales (SAS, AIMS, and BAS) did not increase during treatment. A comparable proportion of patients received antiparkinsonian medication, 30 and 23% in the amisulpride and risperidone groups, respectively (P = 0.21). Patients receiving risperidone experienced an increase in body weight, which was significantly greater than for amisulpride (P = 0.026).
 ...
PMID:Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. 1062 47

The present study utilized factor analysis to investigate possible underlying processes in schizophrenic thought disorder. Using the Communication Disturbances Index [CDI; Arch. Gen. Psychiatry, 53, (1996) 358], a measure of disruption in the communication of meaning from speaker to listener, we examined the speech of 58 stable schizophrenia outpatients for six different types of referential communication disturbances. We calculated instances of disturbance per 100 words and then factor-analyzed our data using the SAS statistical package. Principal components analysis with an oblique rotation produced both a two- and a three-factor solution, depending on factor inclusion criteria. In the three-factor solution, the first two factors reflected weaknesses in language structural organization and in concept-boundary definition, respectively. The third factor appeared to reflect weaknesses in specific facets of memory functioning. In the two-factor solution, the aforementioned structural organization and concept-boundary definition factors were combined into a single executive functioning factor. Results from the study may be heuristic in the development of models of language disturbance in schizophrenia patients.
 ...
PMID:Factor analysis of the Communication Disturbances Index. 1122 20

The -521C/Tsingle nucleotide polymorphism (SNP) in the promoter region of the dopamine D4 receptor gene (DRD4) has recently been detected in oriental (Japanese) individuals and related to novelty seeking and schizophrenia. Here, we report the analysis of the -521C/T polymorphism in a Caucasian (Hungarian) population using two independent genotyping methods. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) procedure utilized the Fspl restriction site around the -521 position. An additional, nonpolymorphic cleavage site was also included into the amplified region to serve as an internal standard for verifying the completion of the digestion. As another independent method, a tetraprimer system for single-tube allele-specific PCR (SAS-PCR) was developed to generate -521C and -521T specific PCR products with different fragment sizes. Consequently, genotyping with SAS-PCR is based on the gel-electrophoretic separation of the allele-specific double-stranded DNA (dsDNA) fragments. 119 healthy Hungarian individuals were genotyped for -521C/T polymorphism of the dopamine D4 promoter region, using both methods. Similar allele frequencies were found (-521C allele: 0.43; -521T allele: 0.57) as reported earlier for the Japanese population.
 ...
PMID:Genotyping the -521C/T functional polymorphism in the promoter region of dopamine D4 receptor (DRD4) gene. 1135 33

Conventional antipsychotic agents can induce extrapyramidal symptoms (EPS) that may be alleviated by switching patients to novel agents such as olanzapine. Patients with schizophrenia and related disorders (ICD-10) who were taking haloperidol (N = 94; mean dose = 12.7 mg/day) and had EPS (Simpson-Angus Scale [SAS] > 3) were directly switched to 6 weeks of open-label olanzapine treatment (mean dose = 11.4 mg/day). There were significant mean improvements (p <0.001 for all measurements) from baseline to endpoint on the SAS (-9.69+/-5.33; percentage change, 87.2%), the Barnes Akathisia Scale (-1.00+/-1.19; percentage change, 82.5%), and the Abnormal Involuntary Movement Scale (-1.48+/-2.89; percentage change, 81.1%), and anticholinergic use decreased from 47.9% to 12.8% (mean baseline to endpoint change: -1.52+/-1.91-mg equivalents of benztropine; p < 0.001). Significant mean baseline to endpoint improvements (p < 0.001 for all measurements) were observed on the Positive and Negative Syndrome Scale (PANSS; -25.28+/-18.67; percentage change, 30.3%), the PANSS-extracted Brief Psychiatric Rating Scale (0-6 scale, -13.41+/-10.16; percentage change, 54.4%), and the Clinical Global Impressions Severity scale (-1.16+/-1.19; percentage change, 26.4%). Spontaneously reported treatment- emergent adverse events with a greater than 5% incidence were somnolence (16.0%), increased appetite (14.9%), weight gain (11.7%), headache (8.5%), anxiety (7.4%), dizziness (6.4%), and insomnia (5.3%). Criteria for a successful switch were met by 90.5% of patients. Psychotic symptom exacerbation was experienced by 30.9% of patients at any time during the study and by 11.7% of patients at endpoint. Results suggest that a direct switch to olanzapine is a therapeutic option when patients with haloperidol-induced EPS are unable to tolerate a more gradual switch.
 ...
PMID:Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. 1147 21


1 2 3 4 Next >>